Overview

Study of DMXAA (Now Known as ASA404) in Solid Tumors

Status:
Completed
Trial end date:
2000-03-01
Target enrollment:
Participant gender:
Summary
This is a phase I study aimed at identifying safe doses of DMXAA in patients with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Cancer Research UK
Collaborator:
Cancer Society Auckland
Treatments:
Acetic Acid
Retinol acetate
Vadimezan